{
    "eid": "2-s2.0-85038366213",
    "title": "Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience",
    "cover-date": "2018-08-09",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "high-dose methotrexate",
        "ifosfamide",
        "Montreal Cognitive Assessment",
        "neurocognitive impairment",
        "non-Hodgkin lymphoma",
        "Primary central nervous system lymphoma",
        "treatment-related neurotoxicity",
        "whole brain radiotherapy"
    ],
    "authors": [
        "Chantiya Chanswangphuwana",
        "Ponlapat Rojnuckarin",
        "Naritsara Cherdchoo",
        "Tassapong Raiyawa",
        "Noppacharn Uaprasert"
    ],
    "citedby-count": 7,
    "ref-count": 33,
    "ref-list": [
        "Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology",
        "Challenges and opportunities in primary CNS lymphoma: a systematic review",
        "Treatment for primary CNS lymphoma: the next step",
        "MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas",
        "High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial",
        "Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma",
        "High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma",
        "Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly",
        "Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)",
        "Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomization of the international extranodal lymphoma study group-32 (IELSG32) phase2 trial",
        "The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma",
        "High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group",
        "R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma",
        "Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter OstdeutscheStudiengruppeH\u00e4mato-Onkologie OSHO-53 phase II study",
        "Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome",
        "High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial",
        "Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma",
        "Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy",
        "High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase II trial 20962",
        "Effects on survival and neurocognitive functions of whole-brain radiotherapy (WBRT) and autologous stem cell transplantation (ASCT) as consolidation options after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary CNS lymphoma (PCNSL): results of the second randomization of the IELSG32 trial",
        "Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines",
        "Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma",
        "Cognitive status and quality of life after treatment for primary CNS lymphoma",
        "The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment",
        "The validity of Thai version of the Montreal Cognitive Assessment",
        "The Montreal Cognitive Assessment: validity and utility in a memory clinic setting",
        "Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma",
        "Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience",
        "Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07",
        "NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report",
        "Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma",
        "Whither whole brain radiotherapy for primary CNS lymphoma?"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60022183",
        "affilname": "King Chulalongkorn Memorial Hospital",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
        "affiliation-country": "Thailand"
    },
    "funding": []
}